Show simple item record

dc.contributor.authorRowan, JAen_NZ
dc.contributor.authorRush, ECen_NZ
dc.contributor.authorPlank, LDen_NZ
dc.contributor.authorLu, Jen_NZ
dc.contributor.authorObolonkin, Ven_NZ
dc.contributor.authorCoat, Sen_NZ
dc.contributor.authorHague, WMen_NZ
dc.date.accessioned2018-09-10T01:52:06Z
dc.date.available2018-09-10T01:52:06Z
dc.date.copyright2018en_NZ
dc.identifier.citationBMJ Open Diabetes Research and Care 2018;6:e000456. doi: 10.1136/bmjdrc-2017-000456
dc.identifier.issn2052-4897en_NZ
dc.identifier.urihttp://hdl.handle.net/10292/11793
dc.description.abstractObjective: To compare body composition and metabolic outcomes at 7-9 years in offspring of women with gestational diabetes (GDM) randomized to metformin (±insulin) or insulin treatment during pregnancy. Research design and methods: Children were assessed at 7 years in Adelaide (n=109/181) and 9 years in Auckland (n=99/396) by anthropometry, bioimpedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI) (n=92/99) and fasting bloods (n=82/99). Results: In the Adelaide subgroup, mothers were similar at enrollment. Women randomized to metformin versus insulin had higher treatment glycemia (p=0.002) and more infants with birth weight >90th percentile (20.7% vs 5.9%; p=0.029). At 7 years, there were no differences in offspring measures. In Auckland, at enrollment, women randomized to metformin had a higher body mass index (BMI) (p=0.08) but gained less weight during treatment (p=0.07). Offspring birth measures were similar. At 9 years, metformin offspring were larger by measures of weight, arm and waist circumferences, waist:height (p<0.05); BMI, triceps skinfold (p=0.05); DXA fat mass and lean mass (p=0.07); MRI abdominal fat volume (p=0.051). Body fat percent was similar between treatment groups by DXA and BIA. Abdominal fat percentages (visceral adipose tissue, subcutaneous adipose tissue and liver) were similar by MRI. Fasting glucose, triglyceride, insulin, insulin resistance, glycosylated hemoglobin (HbA1c), cholesterol, liver transaminases, leptin and adiponectin were similar. Conclusions: Metformin or insulin for GDM was associated with similar offspring total and abdominal body fat percent and metabolic measures at 7-9 years. Metformin-exposed children were larger at 9 years. Metformin may interact with fetal environmental factors to influence offspring outcomes.en_NZ
dc.languageengen_NZ
dc.publisherBMJ Publishing
dc.relation.urihttps://drc.bmj.com/content/6/1/e000456
dc.rights© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
dc.subjectGestational diabetes mellitusen_NZ
dc.subjectInsulinen_NZ
dc.subjectMetforminen_NZ
dc.subjectOffspringen_NZ
dc.titleMetformin in gestational diabetes: The offspring follow-up (MiG TOFU): Body composition and metabolic outcomes at 7-9 years of ageen_NZ
dc.typeJournal Article
dc.rights.accessrightsOpenAccessen_NZ
dc.identifier.doi10.1136/bmjdrc-2017-000456en_NZ
aut.relation.issue1en_NZ
aut.relation.startpagee000456
aut.relation.volume6en_NZ
pubs.elements-id335260
aut.relation.journalBMJ Open Diabetes Res Careen_NZ


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record